Pharmaceuticals News and Research

RSS

Gladstone investigator to receive Essey Award for fight against amyotrophic lateral sclerosis

Shinya Yamanaka, MD, PhD, a senior investigator at the Gladstone Institutes, next month will receive the Essey Award for his "Commitment to a Cure" from The ALS Association Golden West Chapter.

26 Mar 2013

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome.

26 Mar 2013

Viewpoints: Health law offers 'lifeline' to many; National exchange could solve many problems with state insurance; Contrasting looks at faulty hip replacements

Republican leaders in Congress regularly denounce the 2010 Affordable Care Act and vow to block money to carry it out or even to repeal it.

26 Mar 2013

Supreme Court to hear case about 'pay to delay' deals between generic and branded drug makers

Generic and the brand-name drug companies -- usually fierce competitors -- will be on the same side as they argue their case against the federal government.

26 Mar 2013

Two studies shed light on molecular biology of three blood disorders

Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.

26 Mar 2013

First multi-gene DNA sequencing test launched for cancer patients

The first multi-gene DNA sequencing test that can help predict cancer patients' responses to treatment has been launched in the National Health Service, thanks to a partnership between scientists at the University of Oxford and Oxford University Hospitals NHS Trust.

26 Mar 2013

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

25 Mar 2013

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

Pfizer Inc. announced today that the Japanese Ministry of Health, Labor and Welfare has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis who have had an inadequate response to existing therapies.

25 Mar 2013

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

First Edition: March 25, 2013

Today's headlines include reports about the continuing outlook for progress on the federal budget as well as a variety of stories related to the health law's implementation.

25 Mar 2013

Actavis settles patent litigation with AstraZeneca over generic version of Crestor

Actavis, Inc., a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with AstraZeneca resolving outstanding patent litigation related to Actavis' generic version of rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of Crestor tablets, as well as Actavis' rosuvastatin zinc alternate salt product.

25 Mar 2013

Research may offer clues to why esophageal adenocarcinomas rates have increased rapidly

During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA of these esophageal adenocarcinomas has revealed that many share a distinctive mix-up of letters of the genetic code, and found more than 20 mutated genes that had not previously been linked to the disease.

25 Mar 2013

Financial Times special report focuses on tuberculosis

The Financial Times has published a special report, titled "Combating Tuberculosis 2013," as World TB Day on March 24 approaches.

25 Mar 2013

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice of Issuance from the U.S. Patent and Trademark Office for its patent application entitled "ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS", U.S. Patent No.: 8,410,088.

24 Mar 2013

Cocaine can be lethal for people living with HIV

Cocaine, already a damaging drug for those with healthy immune systems, can be lethal for those living with human immunodeficiency virus. Mudit Tyagi, Ph.D., assistant professor of medicine at the George Washington University School of Medicine and Health Sciences, has received two federally funded grants to study how dangerous this combination is in HIV patients.

22 Mar 2013

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Fibromyalgia is a common disorder that is diagnosed in people who have pain in many areas of their body together with important symptoms such as...

22 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

Viewpoints: N.D. abortion law is 'repressive and extreme;' States identify 'promising' ideas to overhaul medical malpractice

Late last week, the North Dakota legislature passed a bill that would ban a woman from having an abortion as soon as the heartbeat of the fetus is detected, which can happen as early as six weeks into a pregnancy.

21 Mar 2013

Researchers develop promising drug candidate to treat psoriasis

Ben-Gurion University of the Negev researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis.

21 Mar 2013

Pharmaceuticals News and Research

Gladstone investigator to receive Essey Award for fight against amyotrophic lateral sclerosis

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Viewpoints: Health law offers 'lifeline' to many; National exchange could solve many problems with state insurance; Contrasting looks at faulty hip replacements

Supreme Court to hear case about 'pay to delay' deals between generic and branded drug makers

Two studies shed light on molecular biology of three blood disorders

First multi-gene DNA sequencing test launched for cancer patients

arGEN-X advances ARGX-112 into formal preclinical development

Japan's MHLW approves XELJANZ for treatment of adults with rheumatoid arthritis

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

First Edition: March 25, 2013

Actavis settles patent litigation with AstraZeneca over generic version of Crestor

Research may offer clues to why esophageal adenocarcinomas rates have increased rapidly

Financial Times special report focuses on tuberculosis

Epizyme receives patent for drug candidate for genetically defined type of non-Hodgkin lymphomas

Cocaine can be lethal for people living with HIV

Fibromyalgia: an interview with Dr Frederick Wolfe, University of Kansas School of Medicine

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Viewpoints: N.D. abortion law is 'repressive and extreme;' States identify 'promising' ideas to overhaul medical malpractice

Researchers develop promising drug candidate to treat psoriasis

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence